ACTRIMS 2022 | Targeting the innate immune system with BTK inhibitors to treat progressive MS

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, discusses the promise of BTK inhibitors for the treatment of multiple sclerosis (MS). A plethora of disease modifying therapies (DMTs) are now available for the treatment of relapsing-remitting MS, acting on inflammatory disease activity. However, the availability of effective therapeutic options targeting progressive neurodegeneration remains a major unmet need. Evidence suggests that BTK inhibitors may additionally target the innate immune system in MS and may therefore show efficacy against progressive disease. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.